Industry News

Search Articles:

XBiotech announces outcome of EMA’s oral explanation meeting
XBiotech announced the EMA rendered a negative “trend” vote after meeting with the Company to discuss the “Day 180 List of Outstanding Issues” related to the Company’s marketing authorization application for its candidate antibody for the treatment of colorectal cancer.April 20, 2017